Literature DB >> 3067545

Is there any place for salmon calcitonin in prevention of postmenopausal bone loss?

J Y Reginster1, R Deroisy, D Denis, M P Lecart, N Sarlet, P Franchimont.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3067545     DOI： 10.3109/09513599809029344

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN： 0951-3590            Impact factor:   2.260


× No keyword cloud information.
  3 in total

1.  Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.

Authors:  M C Ellerington; T C Hillard; S I Whitcroft; M S Marsh; B Lees; L M Banks; M I Whitehead; J C Stevenson
Journal:  Calcif Tissue Int       Date:  1996-07       Impact factor: 4.333

2.  Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.

Authors:  J Y Reginster; S Gaspar; R Deroisy; B Zegels; P Franchimont
Journal:  Osteoporos Int       Date:  1993-09       Impact factor: 4.507

Review 3.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.